Perspective Therapeutics’ VMT-a-NET protocols presented at NANETS sympsium

Perspective Therapeutics announced that two upcoming investigator-initiated trials were presented at the North American Neuroendocrine Tumor Society, NANETS, 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors. Summary: This presentation detailed the planned protocol for the IIT Phase 1 trial of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptors positive tumors to investigate if this new treatment can improve management of patients naive to prior radioligand therapy. The study is an open-label, single arm, single-center, phase 1 trial evaluating the safety, tolerability, and pharmacokinetic properties of the alpha-emitting, systemic radioligand therapy agent Pb-212-VMT-alpha-NET in five different SSTR+ tumors: gastrointestinal neuroendocrine tumors, pheochromocytoma and paraganglioma, small cell lung cancer, renal cell carcinoma, and head and neck. Enrollment for this study is expected to commence in the first quarter of 2024. Presentation Two: Phase 1/2 Trial of Pb-212-VMT-alpha-NET in GI Neuroendocrine Tumors and Pheochromocytoma/Paraganglioma Previously Treated with Radioligand Therapy. Summary: This presentation detailed the planned protocol for the IIT Phase 1/2 trial designed to determine if such a new treatment can improve management of patients who have progressed on beta-emitting radioligand therapy. This study is an open-label, single arm, single-center, Phase 1/2 study evaluating the safety, tolerability, and pharmacokinetic properties of the alpha-emitting, systemic radioligand therapy agent Pb-212-VMT-alpha-NET in somatostatin receptors metastatic GI neuroendocrine tumors and pheochromocytoma/paraganglioma tumors. Enrollment for this study is expected to commence in the first quarter of 2024.